img

Global Oral Vaccine for Human Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Oral Vaccine for Human Market Research Report 2024

Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection. 
According to Mr Accuracy reports’s new survey, global Oral Vaccine for Human market is projected to reach US$ 3746.5 million in 2029, increasing from US$ 2540 million in 2022, with the CAGR of 5.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Vaccine for Human market research.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oral Vaccine for Human market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other

Segment by Application


Public
Private

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oral Vaccine for Human report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Oral Vaccine for Human Market Overview
1.1 Product Overview and Scope of Oral Vaccine for Human
1.2 Oral Vaccine for Human Segment by Type
1.2.1 Global Oral Vaccine for Human Market Value Comparison by Type (2024-2034)
1.2.2 Rotavirus Vaccine
1.2.3 Cholera Vaccine
1.2.4 Oral Polio Vaccine
1.2.5 Other
1.3 Oral Vaccine for Human Segment by Application
1.3.1 Global Oral Vaccine for Human Market Value by Application: (2024-2034)
1.3.2 Public
1.3.3 Private
1.4 Global Oral Vaccine for Human Market Size Estimates and Forecasts
1.4.1 Global Oral Vaccine for Human Revenue 2018-2029
1.4.2 Global Oral Vaccine for Human Sales 2018-2029
1.4.3 Global Oral Vaccine for Human Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Oral Vaccine for Human Market Competition by Manufacturers
2.1 Global Oral Vaccine for Human Sales Market Share by Manufacturers (2018-2024)
2.2 Global Oral Vaccine for Human Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Oral Vaccine for Human Average Price by Manufacturers (2018-2024)
2.4 Global Oral Vaccine for Human Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Oral Vaccine for Human, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Vaccine for Human, Product Type & Application
2.7 Oral Vaccine for Human Market Competitive Situation and Trends
2.7.1 Oral Vaccine for Human Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oral Vaccine for Human Players Market Share by Revenue
2.7.3 Global Oral Vaccine for Human Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oral Vaccine for Human Retrospective Market Scenario by Region
3.1 Global Oral Vaccine for Human Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Oral Vaccine for Human Global Oral Vaccine for Human Sales by Region: 2018-2029
3.2.1 Global Oral Vaccine for Human Sales by Region: 2018-2024
3.2.2 Global Oral Vaccine for Human Sales by Region: 2024-2029
3.3 Global Oral Vaccine for Human Global Oral Vaccine for Human Revenue by Region: 2018-2029
3.3.1 Global Oral Vaccine for Human Revenue by Region: 2018-2024
3.3.2 Global Oral Vaccine for Human Revenue by Region: 2024-2029
3.4 North America Oral Vaccine for Human Market Facts & Figures by Country
3.4.1 North America Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Oral Vaccine for Human Sales by Country (2018-2029)
3.4.3 North America Oral Vaccine for Human Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral Vaccine for Human Market Facts & Figures by Country
3.5.1 Europe Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Oral Vaccine for Human Sales by Country (2018-2029)
3.5.3 Europe Oral Vaccine for Human Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Vaccine for Human Market Facts & Figures by Country
3.6.1 Asia Pacific Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Oral Vaccine for Human Sales by Country (2018-2029)
3.6.3 Asia Pacific Oral Vaccine for Human Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oral Vaccine for Human Market Facts & Figures by Country
3.7.1 Latin America Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Oral Vaccine for Human Sales by Country (2018-2029)
3.7.3 Latin America Oral Vaccine for Human Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Vaccine for Human Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Oral Vaccine for Human Sales by Country (2018-2029)
3.8.3 Middle East and Africa Oral Vaccine for Human Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Vaccine for Human Sales by Type (2018-2029)
4.1.1 Global Oral Vaccine for Human Sales by Type (2018-2024)
4.1.2 Global Oral Vaccine for Human Sales by Type (2024-2029)
4.1.3 Global Oral Vaccine for Human Sales Market Share by Type (2018-2029)
4.2 Global Oral Vaccine for Human Revenue by Type (2018-2029)
4.2.1 Global Oral Vaccine for Human Revenue by Type (2018-2024)
4.2.2 Global Oral Vaccine for Human Revenue by Type (2024-2029)
4.2.3 Global Oral Vaccine for Human Revenue Market Share by Type (2018-2029)
4.3 Global Oral Vaccine for Human Price by Type (2018-2029)
5 Segment by Application
5.1 Global Oral Vaccine for Human Sales by Application (2018-2029)
5.1.1 Global Oral Vaccine for Human Sales by Application (2018-2024)
5.1.2 Global Oral Vaccine for Human Sales by Application (2024-2029)
5.1.3 Global Oral Vaccine for Human Sales Market Share by Application (2018-2029)
5.2 Global Oral Vaccine for Human Revenue by Application (2018-2029)
5.2.1 Global Oral Vaccine for Human Revenue by Application (2018-2024)
5.2.2 Global Oral Vaccine for Human Revenue by Application (2024-2029)
5.2.3 Global Oral Vaccine for Human Revenue Market Share by Application (2018-2029)
5.3 Global Oral Vaccine for Human Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Merck Oral Vaccine for Human Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.2.4 GSK Oral Vaccine for Human Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Sanofi Oral Vaccine for Human Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Corporation Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Lanzhou Institute Oral Vaccine for Human Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Serum Institute
6.5.1 Serum Institute Corporation Information
6.5.2 Serum Institute Description and Business Overview
6.5.3 Serum Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Serum Institute Oral Vaccine for Human Product Portfolio
6.5.5 Serum Institute Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Corporation Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Valneva Oral Vaccine for Human Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Shanghai United Cell
6.6.1 Shanghai United Cell Corporation Information
6.6.2 Shanghai United Cell Description and Business Overview
6.6.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Shanghai United Cell Oral Vaccine for Human Product Portfolio
6.7.5 Shanghai United Cell Recent Developments/Updates
6.8 Bibcol
6.8.1 Bibcol Corporation Information
6.8.2 Bibcol Description and Business Overview
6.8.3 Bibcol Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Bibcol Oral Vaccine for Human Product Portfolio
6.8.5 Bibcol Recent Developments/Updates
6.9 PaxVax
6.9.1 PaxVax Corporation Information
6.9.2 PaxVax Description and Business Overview
6.9.3 PaxVax Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.9.4 PaxVax Oral Vaccine for Human Product Portfolio
6.9.5 PaxVax Recent Developments/Updates
6.10 Vabiotech
6.10.1 Vabiotech Corporation Information
6.10.2 Vabiotech Description and Business Overview
6.10.3 Vabiotech Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Vabiotech Oral Vaccine for Human Product Portfolio
6.10.5 Vabiotech Recent Developments/Updates
6.11 Tiantan Biological
6.11.1 Tiantan Biological Corporation Information
6.11.2 Tiantan Biological Oral Vaccine for Human Description and Business Overview
6.11.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Tiantan Biological Oral Vaccine for Human Product Portfolio
6.11.5 Tiantan Biological Recent Developments/Updates
6.12 EuBiologics
6.12.1 EuBiologics Corporation Information
6.12.2 EuBiologics Oral Vaccine for Human Description and Business Overview
6.12.3 EuBiologics Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.12.4 EuBiologics Oral Vaccine for Human Product Portfolio
6.12.5 EuBiologics Recent Developments/Updates
6.13 Panacea Biotec Ltd
6.13.1 Panacea Biotec Ltd Corporation Information
6.13.2 Panacea Biotec Ltd Oral Vaccine for Human Description and Business Overview
6.13.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio
6.13.5 Panacea Biotec Ltd Recent Developments/Updates
6.14 Bio-Med
6.14.1 Bio-Med Corporation Information
6.14.2 Bio-Med Oral Vaccine for Human Description and Business Overview
6.14.3 Bio-Med Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Bio-Med Oral Vaccine for Human Product Portfolio
6.14.5 Bio-Med Recent Developments/Updates
6.15 Halfkin Bio-Pharmaceuticals
6.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
6.15.2 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Description and Business Overview
6.15.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio
6.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Vaccine for Human Industry Chain Analysis
7.2 Oral Vaccine for Human Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Vaccine for Human Production Mode & Process
7.4 Oral Vaccine for Human Sales and Marketing
7.4.1 Oral Vaccine for Human Sales Channels
7.4.2 Oral Vaccine for Human Distributors
7.5 Oral Vaccine for Human Customers
8 Oral Vaccine for Human Market Dynamics
8.1 Oral Vaccine for Human Industry Trends
8.2 Oral Vaccine for Human Market Drivers
8.3 Oral Vaccine for Human Market Challenges
8.4 Oral Vaccine for Human Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Oral Vaccine for Human Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Oral Vaccine for Human Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Oral Vaccine for Human Market Competitive Situation by Manufacturers in 2022
Table 4. Global Oral Vaccine for Human Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Oral Vaccine for Human Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Oral Vaccine for Human Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Oral Vaccine for Human Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Oral Vaccine for Human Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Oral Vaccine for Human, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Oral Vaccine for Human, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oral Vaccine for Human, Product Type & Application
Table 12. Global Key Manufacturers of Oral Vaccine for Human, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral Vaccine for Human by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Vaccine for Human as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral Vaccine for Human Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Oral Vaccine for Human Sales by Region (2018-2024) & (K Units)
Table 18. Global Oral Vaccine for Human Sales Market Share by Region (2018-2024)
Table 19. Global Oral Vaccine for Human Sales by Region (2024-2029) & (K Units)
Table 20. Global Oral Vaccine for Human Sales Market Share by Region (2024-2029)
Table 21. Global Oral Vaccine for Human Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Oral Vaccine for Human Revenue Market Share by Region (2018-2024)
Table 23. Global Oral Vaccine for Human Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Oral Vaccine for Human Revenue Market Share by Region (2024-2029)
Table 25. North America Oral Vaccine for Human Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Oral Vaccine for Human Sales by Country (2018-2024) & (K Units)
Table 27. North America Oral Vaccine for Human Sales by Country (2024-2029) & (K Units)
Table 28. North America Oral Vaccine for Human Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Oral Vaccine for Human Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Oral Vaccine for Human Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Oral Vaccine for Human Sales by Country (2018-2024) & (K Units)
Table 32. Europe Oral Vaccine for Human Sales by Country (2024-2029) & (K Units)
Table 33. Europe Oral Vaccine for Human Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Oral Vaccine for Human Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Oral Vaccine for Human Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Oral Vaccine for Human Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Oral Vaccine for Human Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Oral Vaccine for Human Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Oral Vaccine for Human Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Oral Vaccine for Human Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Oral Vaccine for Human Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Oral Vaccine for Human Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Oral Vaccine for Human Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Oral Vaccine for Human Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Oral Vaccine for Human Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Oral Vaccine for Human Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Oral Vaccine for Human Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Oral Vaccine for Human Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Oral Vaccine for Human Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Oral Vaccine for Human Sales (K Units) by Type (2018-2024)
Table 51. Global Oral Vaccine for Human Sales (K Units) by Type (2024-2029)
Table 52. Global Oral Vaccine for Human Sales Market Share by Type (2018-2024)
Table 53. Global Oral Vaccine for Human Sales Market Share by Type (2024-2029)
Table 54. Global Oral Vaccine for Human Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Oral Vaccine for Human Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Oral Vaccine for Human Revenue Market Share by Type (2018-2024)
Table 57. Global Oral Vaccine for Human Revenue Market Share by Type (2024-2029)
Table 58. Global Oral Vaccine for Human Price (US$/Unit) by Type (2018-2024)
Table 59. Global Oral Vaccine for Human Price (US$/Unit) by Type (2024-2029)
Table 60. Global Oral Vaccine for Human Sales (K Units) by Application (2018-2024)
Table 61. Global Oral Vaccine for Human Sales (K Units) by Application (2024-2029)
Table 62. Global Oral Vaccine for Human Sales Market Share by Application (2018-2024)
Table 63. Global Oral Vaccine for Human Sales Market Share by Application (2024-2029)
Table 64. Global Oral Vaccine for Human Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Oral Vaccine for Human Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Oral Vaccine for Human Revenue Market Share by Application (2018-2024)
Table 67. Global Oral Vaccine for Human Revenue Market Share by Application (2024-2029)
Table 68. Global Oral Vaccine for Human Price (US$/Unit) by Application (2018-2024)
Table 69. Global Oral Vaccine for Human Price (US$/Unit) by Application (2024-2029)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Merck Oral Vaccine for Human Product
Table 74. Merck Recent Developments/Updates
Table 75. GSK Corporation Information
Table 76. GSK Description and Business Overview
Table 77. GSK Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. GSK Oral Vaccine for Human Product
Table 79. GSK Recent Developments/Updates
Table 80. Sanofi Corporation Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Sanofi Oral Vaccine for Human Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Lanzhou Institute Corporation Information
Table 86. Lanzhou Institute Description and Business Overview
Table 87. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Lanzhou Institute Oral Vaccine for Human Product
Table 89. Lanzhou Institute Recent Developments/Updates
Table 90. Serum Institute Corporation Information
Table 91. Serum Institute Description and Business Overview
Table 92. Serum Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Serum Institute Oral Vaccine for Human Product
Table 94. Serum Institute Recent Developments/Updates
Table 95. Valneva Corporation Information
Table 96. Valneva Description and Business Overview
Table 97. Valneva Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Valneva Oral Vaccine for Human Product
Table 99. Valneva Recent Developments/Updates
Table 100. Shanghai United Cell Corporation Information
Table 101. Shanghai United Cell Description and Business Overview
Table 102. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Shanghai United Cell Oral Vaccine for Human Product
Table 104. Shanghai United Cell Recent Developments/Updates
Table 105. Bibcol Corporation Information
Table 106. Bibcol Description and Business Overview
Table 107. Bibcol Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Bibcol Oral Vaccine for Human Product
Table 109. Bibcol Recent Developments/Updates
Table 110. PaxVax Corporation Information
Table 111. PaxVax Description and Business Overview
Table 112. PaxVax Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. PaxVax Oral Vaccine for Human Product
Table 114. PaxVax Recent Developments/Updates
Table 115. Vabiotech Corporation Information
Table 116. Vabiotech Description and Business Overview
Table 117. Vabiotech Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Vabiotech Oral Vaccine for Human Product
Table 119. Vabiotech Recent Developments/Updates
Table 120. Tiantan Biological Corporation Information
Table 121. Tiantan Biological Description and Business Overview
Table 122. Tiantan Biological Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Tiantan Biological Oral Vaccine for Human Product
Table 124. Tiantan Biological Recent Developments/Updates
Table 125. EuBiologics Corporation Information
Table 126. EuBiologics Description and Business Overview
Table 127. EuBiologics Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. EuBiologics Oral Vaccine for Human Product
Table 129. EuBiologics Recent Developments/Updates
Table 130. Panacea Biotec Ltd Corporation Information
Table 131. Panacea Biotec Ltd Description and Business Overview
Table 132. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Panacea Biotec Ltd Oral Vaccine for Human Product
Table 134. Panacea Biotec Ltd Recent Developments/Updates
Table 135. Bio-Med Corporation Information
Table 136. Bio-Med Description and Business Overview
Table 137. Bio-Med Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Bio-Med Oral Vaccine for Human Product
Table 139. Bio-Med Recent Developments/Updates
Table 140. Halfkin Bio-Pharmaceuticals Corporation Information
Table 141. Halfkin Bio-Pharmaceuticals Description and Business Overview
Table 142. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product
Table 144. Halfkin Bio-Pharmaceuticals Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Oral Vaccine for Human Distributors List
Table 148. Oral Vaccine for Human Customers List
Table 149. Oral Vaccine for Human Market Trends
Table 150. Oral Vaccine for Human Market Drivers
Table 151. Oral Vaccine for Human Market Challenges
Table 152. Oral Vaccine for Human Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Oral Vaccine for Human
Figure 2. Global Oral Vaccine for Human Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Oral Vaccine for Human Market Share by Type in 2022 & 2029
Figure 4. Rotavirus Vaccine Product Picture
Figure 5. Cholera Vaccine Product Picture
Figure 6. Oral Polio Vaccine Product Picture
Figure 7. Other Product Picture
Figure 8. Global Oral Vaccine for Human Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Oral Vaccine for Human Market Share by Application in 2022 & 2029
Figure 10. Public
Figure 11. Private
Figure 12. Global Oral Vaccine for Human Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Oral Vaccine for Human Market Size (2018-2029) & (US$ Million)
Figure 14. Global Oral Vaccine for Human Sales (2018-2029) & (K Units)
Figure 15. Global Oral Vaccine for Human Average Price (US$/Unit) & (2018-2029)
Figure 16. Oral Vaccine for Human Report Years Considered
Figure 17. Oral Vaccine for Human Sales Share by Manufacturers in 2022
Figure 18. Global Oral Vaccine for Human Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Oral Vaccine for Human Players: Market Share by Revenue in 2022
Figure 20. Oral Vaccine for Human Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Oral Vaccine for Human Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Oral Vaccine for Human Sales Market Share by Country (2018-2029)
Figure 23. North America Oral Vaccine for Human Revenue Market Share by Country (2018-2029)
Figure 24. United States Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Oral Vaccine for Human Sales Market Share by Country (2018-2029)
Figure 27. Europe Oral Vaccine for Human Revenue Market Share by Country (2018-2029)
Figure 28. Germany Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Oral Vaccine for Human Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Oral Vaccine for Human Revenue Market Share by Region (2018-2029)
Figure 35. China Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Southeast Asia Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Latin America Oral Vaccine for Human Sales Market Share by Country (2018-2029)
Figure 43. Latin America Oral Vaccine for Human Revenue Market Share by Country (2018-2029)
Figure 44. Mexico Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Brazil Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Argentina Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Oral Vaccine for Human Sales Market Share by Country (2018-2029)
Figure 48. Middle East & Africa Oral Vaccine for Human Revenue Market Share by Country (2018-2029)
Figure 49. Turkey Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. UAE Oral Vaccine for Human Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Global Sales Market Share of Oral Vaccine for Human by Type (2018-2029)
Figure 53. Global Revenue Market Share of Oral Vaccine for Human by Type (2018-2029)
Figure 54. Global Oral Vaccine for Human Price (US$/Unit) by Type (2018-2029)
Figure 55. Global Sales Market Share of Oral Vaccine for Human by Application (2018-2029)
Figure 56. Global Revenue Market Share of Oral Vaccine for Human by Application (2018-2029)
Figure 57. Global Oral Vaccine for Human Price (US$/Unit) by Application (2018-2029)
Figure 58. Oral Vaccine for Human Value Chain
Figure 59. Oral Vaccine for Human Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries